Companies · Biotechnology

Sound Pharmaceuticals Inc

SEATTLE · Biotechnology

Diligence memoA one-page analyst read on Sound Pharmaceuticals Inc — recommendation, valuation, rhythm, risks.
$21.6M
Total raised · real
4
Rounds
2.1×
Latest step-up
Top 32%
Sector rank · raised
Series A
Latest stage · inferred · Thu May 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Sound Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.44× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
  • Within the normal band (144% of peer median) for its niche.
Dormant
  • Last raise 8.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Sound Pharmaceuticals Inc is one of 4293 Biotechnology companies tracked from SEATTLE. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
5
Investors (latest)
2018-05-24
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2005-05-10 Raised $7.6M (real) Modeled valuation $273M (est)$7.6M$273MSeries A2005Series A · 2012-12-05 Raised $1.5M (real) Modeled valuation $55M (est)$1.5M$55MSeries A2012Pre-Seed · 2015-08-07 Raised $300K (real) Modeled valuation $17M (est)$300K$17MPre-Seed2015Series A · 2015-08-07 Raised $4.1M (real) Modeled valuation $148M (est)$4.1M$148MSeries A2015Series A · 2018-05-24 Raised $8.4M (real) Modeled valuation $304M (est)$8.4M$304MSeries A2018+$1.5M+$300K+$4.1M+$8.4MCumulative $22M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$7.6M · 2005
Series A extension$1.5M · 2012
Bridge · Series A-stage$300K · 2015smaller follow-on
Series A extension$4.1M · 2015
Series A extension$8.4M · 2018

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$304.0M
Base estimate est.
$9.2M
Conservative case
$1.7B
Upside case
$38.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $273.4M · 2005-05-102005Series A · modeled $54.8M · 2012-12-05Pre-Seed · modeled $16.6M · 2015-08-07Series A · modeled $148.2M · 2015-08-07Series A · modeled $304.0M · 2018-05-242018
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
8.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
39 mo
Avg between rounds
$1.7M/yr
Capital velocity
21.1 yr
On record since
2005
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.0× above median
This company$21.6M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.5× above median
This company$8.4M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 4.7× above median
This company$304.0M
Sector median$64.2M

Raised more than 69% of sector peers (real $). Modeled value above 77% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #40 of 157.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Bio-Dent, LTD. LLC · Series A Raised $15.0M · modeled $542.3M (est)Anthera Pharmaceuticals Inc · Series A Raised $15.0M · modeled $542.3M (est)Cynvec LLC · Series A Raised $17.4M · modeled $542.3M (est)Biothera Holding Corp. · Series A Raised $16.2M · modeled $529.3M (est)Limelight Bio, Inc. · Series A Raised $14.0M · modeled $506.2M (est)Overture Life, Inc. · Series A Raised $13.6M · modeled $491.7M (est)TAI Diagnostics, Inc. · Series A Raised $21.1M · modeled $463.8M (est)Occulo Holdings LLC · Series A Raised $12.8M · modeled $462.7M (est)Agilis Biotherapeutics, Inc. · Series A Raised $25.7M · modeled $458.0M (est)CAMBRIDGE EPIGENETIX Ltd · Series A Raised $12.3M · modeled $444.4M (est)Genten Therapeutics, Inc. · Series A Raised $12.0M · modeled $433.8M (est)LTC BioSciences, Inc · Series A Raised $12.0M · modeled $433.8M (est)Sound Pharmaceuticals Inc (this company) Raised $21.6M · modeled $304.0M (est)Sound Pharmaceuticals Inc
CompanyStageRaised · realValue · estvs peer med.
Bio-Dent, LTD. LLCSeries A$15.0M$542.3M2.57×
Anthera Pharmaceuticals IncSeries A$15.0M$542.3M2.57×
Cynvec LLCSeries A$17.4M$542.3M2.57×
Biothera Holding Corp.Series A$16.2M$529.3M2.51×
Limelight Bio, Inc.Series A$14.0M$506.2M2.40×
Overture Life, Inc.Series A$13.6M$491.7M2.33×
TAI Diagnostics, Inc.Series A$21.1M$463.8M2.20×
Occulo Holdings LLCSeries A$12.8M$462.7M2.19×
Agilis Biotherapeutics, Inc.Series A$25.7M$458.0M2.17×
CAMBRIDGE EPIGENETIX LtdSeries A$12.3M$444.4M2.11×
Genten Therapeutics, Inc.Series A$12.0M$433.8M2.06×
LTC BioSciences, IncSeries A$12.0M$433.8M2.06×
Sound Pharmaceuticals Inc this companySeries A$21.6M$304.0M1.44×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$7.6M2005-05-10$34.4M$273.4M85%
Series A$1.5M2012-12-05$6.9M$54.8M85%
Pre-Seed$300K2015-08-07$1.7M$16.6M85%
Series A$4.1M2015-08-07$18.6M$148.2M85%
Series A$8.4M2018-05-24$38.2M$304.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$7.6M2005-05-10
    • First recorded raise — entered as Series A.
    • 21 investors on this round.
  2. Series A$1.5M2012-12-05
    • Raised again after 91 mo — slower than the ~14 mo sector norm.
    • Round 5.0× smaller than the prior — bridge or down round.
    • Switched to Rule 06 (was Rule 506(b)).
    • 9 investors on this round.
  3. Pre-Seed$300K2015-08-07
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round 5.1× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 1 investor on this round.
  4. Series A$4.1M2015-08-07
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 13.7× larger than the prior — scaling up.
    • 4 investors on this round.
  5. Series A$8.4M2018-05-24
    • Raised again after 34 mo — slower than the ~14 mo sector norm.
    • Round 2.1× larger than the prior — scaling up.
    • 5 investors on this round.
Intelligence
2021 ~Q3
Modeled next raise · ~39mo cadence
$17.2M
Modeled next size est.range $11.2M$27.6M
2.1×
Last step-up
$1.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Guyer7 other2018-05
James C. Towne3 other2018-05
James Paul Rickey2 other2015-08
Joseph Ashley2 other2005-05
Paul Thompson2 other2005-05
Glenn Kawasaki1 other2005-05
John C. Sullivan1 other2018-05
Eric Lynch2005-05
Jonathan Kil2005-05
Registry & provenance

Sound Pharmaceuticals Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1165353
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Nano Precision Medical, Inc.BiotechnologySeries A$22.1M$206.7Msame sector · same stage
GnuBIO Inc.BiotechnologySeries A$21.0M$361.5Msame sector · same stage
CyVek, Inc.BiotechnologySeries A$22.3M$361.5Msame sector · same stage
Seahorse Bioscience IncBiotechnologySeries A$20.7M$410.2Msame sector · same stage
Axion BioSystems, Inc.BiotechnologySeries A$20.6M$289.2Msame sector · same stage
Mammoth Biosciences, Inc.BiotechnologySeries A$20.6M$267.9Msame sector · same stage
GENVAULT CorpBiotechnologySeries A$20.4M$245.9Msame sector · same stage
Aviir IncBiotechnologySeries A$22.9M$361.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
MuscleSound, Inc.BiotechnologySeed$964K87%
Cellsound Aesthetics LTDBiotechnologySeed$29.3M86%
Otolith Sound, Inc.BiotechnologySeries B$33.8M86%
SoundPipeBiotechnologyPre-Seed$4.1M86%
Otologic Technologies, Inc.BiotechnologyPre-Seed$1.1M86%
BioPhoundry, Inc.BiotechnologySeed$4.3M84%
Biocurity Pharmaceuticals Inc.BiotechnologySeed$13.3M84%
OraLiva, Inc.BiotechnologySeed$5.1M84%
Frequently asked
How much funding has Sound Pharmaceuticals Inc raised?
Sound Pharmaceuticals Inc has raised approximately $21.6M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Sound Pharmaceuticals Inc's estimated valuation?
Provath's modeled valuation for Sound Pharmaceuticals Inc is approximately $304.0M (modeled range $9.2M–$1.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Sound Pharmaceuticals Inc at?
Sound Pharmaceuticals Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Thu May 24.
What does Sound Pharmaceuticals Inc do and where is it based?
Sound Pharmaceuticals Inc operates in the Biotechnology sector, based in SEATTLE.
Explore related

See where Sound Pharmaceuticals Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Sound Pharmaceuticals Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.